TTrialPathMatch Me to Trials
← Back to trials
RecruitingPulmonary HypertensionPulmonary Vascular DiseaseLeft Heart Disease

Pulmonary Hypertension in Left Heart Disease

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.

Sponsor: Mayo Clinic

You may qualify if…

  • ✓ Patients referred to the cardiac catheterization laboratory for invasive right heart catheterization for any reason.
  • ✓ Left Heart Disease, defined as one (or more) of the following:
  • ✓ Symptomatic HFpEF, defined by signs and symptoms of HF (dyspnea, fatigue), normal left ventricular (LV) EF (≥50% within 12 months of enrollment), and objective evidence of HF fulfilling at least one of the following criteria: Prior hospitalization for decompensated HF treated with intravenous diuretics; Invasively verified HFpEF defined by pulmonary capillary wedge pressure (PCWP) of ≥15 mmHg at rest and/or ≥25 mmHg during exercise; Clinical diagnosis of HFpEF that does not meet criteria i. or ii. but verified with NTproBNP\>300 pg/ml in sinus rhythm or \>900 pg/ml in AF; H2FPEF score ≥6 or HFA-PEFF score≥5 according to current guidelines.
  • ✓ Symptomatic HFrEF, defined by defined by signs and symptoms of HF (dyspnea, fatigue) and reduced EF (\<50%).
  • ✓ Symptomatic valvular heart disease (VHD), defined by signs and symptoms of HF (dyspnea, fatigue) in tandem with clinically significant aortic or mitral valve disease (regurgitation and/or stenosis).

You may not qualify if…

  • ✕ Patient inability or unwillingness to undergo noninvasive echocardiography, or if echocardiography would, in the opinion of the investigator, somehow compromise the quality of data acquisition for the clinical case.
  • ✕ WSPH Group 1 Pulmonary hypertension or PH (Pulmonary arterial hypertension; including congenital heart disease)
  • ✕ Group 3 PH (Hypoxia/Lung disease-related PH)
  • ✕ Group 4 PH (Thromboembolic PH)
  • ✕ Group 5 PH (Miscellaneous)
  • ✕ Clinically significant parenchymal lung disease, hypoxemia, or lung infection
  • ✕ Amyloid/infiltrative cardiomyopathy
  • ✕ Acute Myocarditis

Where it's recruiting

Minnesota

Rochester

Source: ClinicalTrials.gov · NCT05935605 · last updated 2026-03-05

Pulmonary Hypertension in Left Heart Disease · TrialPath